As of June 19, 2025, Deciphera Pharmaceuticals Inc (DCPH) reports a Gross Margin of 97.72%.
Gross Margin indicates the portion of sales revenue remaining after covering production costs, highlighting operational efficiency.
Historical Trend of Deciphera Pharmaceuticals Inc's Gross Margin
Over recent years, Deciphera Pharmaceuticals Inc's Gross Margin has shown a stable trend. The table below summarizes the historical values:
| Date | Gross Margin |
|---|---|
| 2023-12-31 | 97.72% |
| 2022-12-31 | 93.46% |
| 2021-12-31 | 96.95% |
| 2020-12-31 | 99.47% |
This slight downward trend highlights how Deciphera Pharmaceuticals Inc manages its operational efficiency and pricing power over time.
Comparing Deciphera Pharmaceuticals Inc's Gross Margin to Peers
To better understand Deciphera Pharmaceuticals Inc's position, it's useful to compare its Gross Margin against industry peers. Below are selected comparisons:
| Company | Gross Margin |
|---|---|
| Deciphera Pharmaceuticals Inc (DCPH) | 97.72% |
| Neoimmunetech Inc (950220.KQ) | 7775.20% |
| Seres Therapeutics Inc (MCRB) | 7775.20% |
| Bioatla Inc (BCAB) | 7775.20% |
| Allovir Inc (ALVR) | 7775.20% |
| Arcus Biosciences Inc (RCUS) | 7775.20% |
Compared to its competitors, Deciphera Pharmaceuticals Inc's Gross Margin is about average compared to peers, indicating industry-standard operational efficiency.